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Betulinic Acid (BA) is a widely available plant-derived triterpene reported as a selective 
cytotoxic activity against cancer cell of neuroectodermal origin and leukaemias. 
Interestingly, this will be first report to demonstrate the cytotoxic effect of BA in VSMCs. 
First, MTT cytotoxic assay was used to measure cell viability of VSMCs with 
predetermined concentrations of BA for 24h, 48h and 72h. The results obtain indicated that 
BA inhibit the growth and proliferation of VSMCs in a dose dependent manner IC10 of 
0.4µg/ml, IC25 of 1µg/ml and IC50 of 3.8 µg/ml significantly (P<0.05). Secondly, the 
genotoxic potential associated to exposure to BA was assessed on VSMCs in vitro by the 
comet assay. BA exhibits low level of DNA damage and not likely to increase the level of 
DNA damage after 24 h exposure. Moreover, Flow cytometric analysis revealed that BA 
treatment FOR 24 h induced cell cycle arrest at the G1 phase and caused the appearance of 
a sub-G1 DNA peak at 48 h. Finally, the cell death morphology indicates that the 
percentage of apoptotic at 24 h were 12.43 ± 1.55% and at 48 h were 23.17 ± 1.73%, the 
percentage of necrotic cells at 48 h were 14.63 ± 1.45%. An increase percentage of 
apoptotic cells at 72 h were 45.92 ± 1.45%. In conclusion, exposure of BA to VSMCs 
initiate early DNA damage, arrest at G1 phase and induce apoptosis. 
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Betulinic Acid (BA) merupakan extrak triterpene daripada tumbuhan yang menunjukan 
aktiviti sitotoksik terhadap sel kanser neuroekotoderma dan lekumia. Ini ialah kajian 
pertama yang meneliti kesan sitotoksik terhadap cell otot licin vascular (VSMCs). 
Peneletian assai sitotoksik MTT pada masa 24, 48 dan 72 jam menunjukkan nilai dos BA 
yang merencat pertumbuhan dan proliferasi VSMCs ialah IC10 of 0.4µg/ml, IC25 = 1µg/ml 
dan IC50 = 3.8 µg/ml pada aras signifikan (P<0.05). Sementara itu BA menunjukkan kesan 
genotoksik yang kurang pada masa 4 jam dan tidak meningkatkan kesan genotoksiknya 
pada masa rawatan 24 jam. BA juga merencat kitaran sel pada fasa G1dalam tempoh 24 
jam dan meningkatkan fasa sub-G pada 48 jam, kajian ini dikenalpasti dengan  
menggunakan teknik sitometri aliran. Akhirnya, peratus kematian sel pada 24 jam didapati 
12.43 ± 1.55% dan pada 48 jam ialah 23.17 ± 1.73%, manakala peratus kematian cell 
melalui proses nekrotic ialah 14.63 ± 1.45% pada 48 jam. Seterusnya, peningkatan peratus 
kematial cell melalui proses apoptosis didapati 45.92 ± 1.45% pada masa 72 jam. 
Kesimpulanya, kesan BA terhadap VSMCs menunjukan kerosakan DNA pada peringkat 
awal dan seterusnya mencetus serangan cell pada fasa G1 dan diikuti oleh kematian sel 
melalui proses apoptosis. 
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CHAPTER 1 
 
1 INTRODUCTION 
 
1.1 Background 
 
Cardiovascular diseases continue to be the major hospital admissions and death in 
government hospitals in Malaysia (Anas et al., 2008). The trend in the prevalence of 
coronary artery disease (CAD) associated with artheriochelorosis is believed to be 
increasing in Malaysia although limited epidemiological data are presently available. 
According to Khoo et al, (1991) cardiovascular diseases occupied third place as the cause 
of death from 1950 to 1989. An ethnical based study from Chiam et al, (2002) indicates 
that the prevalence of combinations of hypertension and hyperlipidaemia among patients 
undergone coronary artery bypass grafting (CABG) in Hospital Universiti Kebangsaan 
Malaysia were 46.0% Chinese, 40.1% Malays and 11.6% Indians. Recently, Shahar et al, 
(2007) indicated that almost 80% of Malaysian men have higher total cholesterol and 
LDL-cholesterol and at high risk of CAD. 
 
Atherosclerosis involves the proliferation of smooth muscle cells and the accumulation of 
lipids and other major causative factors in the pathogenesis of coronary artery disease 
(CAD) and restenosis after angioplasty. The widely used treatment for CAD complication 
is Percutaneous Transluminal Coronary Angioplasty (PTCA), which was employed to 
enlarge obstructed coronary artery. However, overshadowing of PTCA was the major 
cause of angiographic restenosis and periodically similar symptoms at 6 months. Ozaki et 
al,1996 estimated restenosis rates at 12.7%, 43%, 49.4% and 52.5% at 1, 3, 6 and 12 
months respectively.  This occurrence is due to the adverse effect of PTCA procedure 
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which cause lesion to the aerial wall. Injured arterial wall secretes procrine and autocrine 
molecules which alter the cell cycle phase and phenotypic structure of Vascular Smooth 
Muscle Cells (VSMCs). The proliferation and migration of VSMCs are the major attributes 
for the narrowing of the artery lumen. This occurrence is described as restenosis. 
 
Intracoronary stent was introduced to reduce the rate of angiographic and clinical 
restenosis compared to percutaneous transluminal coronary angioplasty (PTCA) alone. 
These methods imply by using a “stent” a metal bar accompanied together with PTCA 
procedure in odder to impede thinking of the neointima layer of the artery. However, stent 
placement also contributes to in-stent restenosis. New tissues favorably grow inside the 
stent because the stent is placed rigidly attached to blood vessel. Initially, this new tissue 
consists of healthy VSMCs and endothelium cells from the lining of the arterial wall. This 
is a constructive effect because development of normal lining over the stent allows blood to 
flow smoothly over the stented area without clotting. However, in about 25% of patients 
the appearance of scar underneath the lining of the artery may become so thick that it can 
obstruct the blood flow and produce an important blockage. In-stent restenosis is typically 
seen 3 to 6 months after the procedure; after 12 months have passed uneventfully, it is rare.  
 
Recently, an improved outcome with using an attractive alternative to bare-metal stents is 
drug eluting stent. This is a promising new treatment involve coating the outer aspect of a 
standard coronary stent with a thin polymer containing medication that can prevent the 
formation of scar tissue at the site of coronary intervention. Currently, two drug-eluting 
stents used widely are Sirolimus-Eluting Balloon, and Paclitaxel Eluting Stent (TAXUS)-
IV. Both These techniques demonstrated striking reductions in angiographic restenosis and 
revascularization rates with sirolimus- and paclitaxel-eluting stents, respectively. However, 
comparative clinical trials have shown that drug eluting stent do not confer any benefit in 
3 
 
clinical outcomes (Grube et al., 2002) and may even predispose to stent thrombosis ( Rhee 
et al.,2008). Furthermore, the impediment to the widespread adoption of drug-eluting 
stents is the high cost (Bakhai et al., 2003). Therefore, an alternative method the prevent 
restenosis after PTCA will be interesting. 
 
In the last decade the implication of natural compounds in controlling the proliferation and 
migration of neointima in diseased arthery has become evident. Alternative to Paclitaxel 
and Sirolimus, the search of other natural substances will become a useful for the treatment 
of restenosis by prevailing over the complications and obstruction of DEC application. 
Interestingly, there are various natural compounds such as Emodin (Heo et al., 2008), 
Raphanus sativus extract (Suh et al., 2006), that have great potential to inhibit the growth 
of VSMCs and induce apoptosis. Although DES limits restenosis, adverse vascular 
pathologies and toxicities continue to be of major concern. Higher concentration of 
paclitaxel may lead to increased apoptosis in the vessel wall and consequently to a more 
unstable phenotype of the pre-existing atherosclerotic lesion (Shishehbor et al., 2008). 
Whereas, sirolimus-eluting stents was not shown to effect on arterial pathology but it was 
described temporarily lead to systemic concentrations that approach immunosuppressive 
levels (Sousa et al., 2001). Thus, application of a non toxic anti proliferative and anti 
migratory compound will be interesting to prevent restenosis. 
 
In this regard, the Betulinic acid (BA) (3β-hydroxy-lup-20(29)-en-28-oic acid), a 
pentacyclic lupane triterpene, has shown potential in inducing cell cycle arrest and 
apoptosis in various cancer cell. Convincingly, BA has advantages such as non toxic 
compound (Alakurtti et al., 2006) with ability to decrease cyclin D1 and Bcl gene 
expression, and induce apoptosis through p53-independent pathway. Thus, BA is 
considerately involved to inhibit VSMCs proliferation, migration and induce apoptosis. 
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Vascular smooth muscle cells (VSMCs) are the prime cellular component of the normal 
artery as well as of intimal lesions that develop in response to arterial injury. Consequently, 
proliferation and migration of VSMCs are hallmarks of vascular disorders such as 
atherosclerosis and restenosis (Dzau et al., 2002). The purpose of this study was to 
investigate the effects of BA on VSMC proliferation and migration. To achieve these aims 
VSMCs cultures were used to access the cytotoxicity, potential of growth inhibition, 
genotoxicity and induction of apoptosis by BA. 
 
1.2 Objective of the study 
 
The aims of the present study were, first, to elucidate whether BA is able to attenuate 
VSMC growth and proliferation in vitro. 
Specifically, the present thesis aimed at 
 
• To study the potential of BA to reduce cell viability and inhibit growth arrest. 
 
• To evaluate the level of genotoxic effect of BA in VSMCs. 
 
• To elecidate the mode of cell cycle arrest. 
 
• To confirm the mode of cell death. 
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CHAPTER 2 
 
 
2 LITERATURE REVIEW 
 
2.1 The Percutanueous Transluminal Coronary Angioplasty 
 
Percutanueous Transluminal Coronary Angioplasty (PTCA) has been established since 
1978 by Andreas Gruentzig (Landzberg et al., 1997) for treating progressive 
atherosclerosis which leads to the formation of fibrous plaques and accompanied by 
narrowing of artery. This technique is widely used as a non-surgical revascularization 
procedure that involves opening obstructed coronary arteries for patients with coronary 
artery disease. It provides feasible alternative to coronary artery bypass graft (CABG) 
surgery as shown in Figure 2.1. 
 
The physical force exerted by the inflated balloon catheter on the artery wall causes 
distention of the vessel resulting in luminal diameter gain and improved vessel patency and 
hence the blood flow to the myocardium (Libby. 2002). Despite of substantial clinical and 
economical advances in PTCA, the major limitation of this procedure is restenosis of the 
target vessel, manifesting as late arterial renarrowing at the site of intervention. Several 
studies indicated that restenosis rate were 15%, (Lokito et al., 2000) and 27%, (Cultip. 
2006) during first 6 months after PTCA, other complications were reported as rapid closure 
and acute closure that can often lead to myocardial infarction, the need for emergency 
bypass surgery, or even death. Therefore, a metallic stent can be placed in the artery after 
balloon dilatation, in which case intensive anti platelet therapy and low dose aspirin is 
required for four weeks after the procedure (Gaspardone et al., 2005). This coronary stents 
procedure has not shown a promising impact on the clinical effectiveness, in reducing 
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abrupt vessel closure and restenosis. The stent is a foreign object and it stimulates an 
immune response. This may cause scar tissue (cell proliferation) to rapidly grow over the 
stent. In addition, there is a strong tendency for clots to form at the site where the stent 
damages the arterial wall.  
 
The excessive scar tissue in the luminal wall of the coronary artery, results in neointimal 
hyperplasia (proliferation and migration of vascular smooth muscle cells and production of 
extracellular matrix). Coincidentally, the long term clinical outcome of stent implantation 
continues repeat renarrowing by a process called in stent restenosis ISR (Pendyala et al., 
2008). Clinically ISR is still unacceptably high and has been shown to occur in 15% to 
30% of people implanted with bare metal stents. The increase of extracellular matrix 
formation appears to form the bulk of the neointimal hyperplasia tissue in the lumen. 
Currently, prevention of ISR is accentuated by producing a stent that has potential to 
initiate the tissue response or any such pretreated stents need to be safe, user friendly, and 
not to add significantly to the cost or time required for the procedure. Interest has focused 
on ablative techniques as an alternative to balloon angioplasty (Figure 2.2). 
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Figure 2.1 Plaque buildup artery is deflated with balloon catheter.  
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Figure 2.2 Restenosis of a stent-widened coronary artery.The illustration shows the 
restenosis of a stent-widened coronary artery. With expanded stent compresses plaque, 
allowing normal blood flow. 
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Recently, drug-eluting stents were designed to lessen this problem; by coating an 
antiproliferative drug can sucessfully avoid this in-stent restenosis. The first successful 
Drug-eluting stent approved by Food and Drug Administration (FDA) was sirolimus-
eluting stents in 2003 (Thompson. 2003). Soon thereafter a series of trials of paclitaxel-
eluting stents led to FDA approval of the Taxus stent in 2004 (DeJohn. 2004). 
 
Interestingly, (DES) procedure associated with antithrombus therapies has dramatically 
decreased the mortality and morbidity in patients and have resulted in fairly low restenosis 
rates of <5% (Medina and Foto. 2004). The strategies to reduce in-stent restenosis by 
employing DES can be categorized into 3 processes: (1) inhibition of cell cycle entry by 
cytostatic drug with focus in arresting cell cycle at Go/G1; (2) cytotoxic strategies, which 
induce the death of cells that enter the cell cycle but not necrosis ;(3) paracrine strategies, 
which inhibits down stream signiling involve in the progression of restenosis, such as 
antithrombosis and re-endothelialization, and inhibits vascular smooth muscle cell (VSMC) 
proliferation (eg, inhibiting TNF-α ). At present, rapamycin and paclitaxel are the most 
clinically proven and predominantly used drugs in DES. They show promising evidence in 
inhibits cell cycle progression at the late G1 and M phases, respectively (Wessely et al., 
2007).However, comparative clinical trials have shown no difference in patient outcomes, 
and drug-eluting stents are considerably more expensive than their bare-metal counterparts. 
Furthermore, observational clinical studies have shown that patients with diabetes have 
less favorable results after percutaneous coronary intervention compared with the non 
diabetic counterparts, but its mechanism remains unclear. 
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2.2 Mechanism of In-Stent Restenosis (ISR) 
 
2.2.1 The arterial wall 
 
Healthy arteries typically consist of three layers, the tunica intima, tunica media and tunica 
adventia. The intima comprises a continuous monolayer of tightly connected endothelial 
cells lying on a basement membrane within an interstitial matrix containing laminin and 
heparin sulphate proteoglycans. Tunica media is the thickest layer of the blood vessel and 
is comprised of vascular smooth muscle cells (VSMC), elastin, collagen, and other 
extracellular matrix components. The adventitia comprises loose connective tissue, 
capillaries, fibroblasts and fat cells separated from the outer media by an external elastic 
lamina.  
 
2.2.2 Cellular events following angioplasty 
 
Overstretching of the artery during balloon angioplasty and stenting results in dissection of 
the arterial media, endothelial damage, and fracturing of the arterial internal elastic lamina. 
Additionally, arterial lesion reflects a cascade of molecular and cellular events within the 
vascular wall which results in the release of numerous vasoactive, thrombogenic, cytokines 
and mitogenic factors. These phenomena involve both an acute and chronic phase. The 
early event of acute phase is elastic recoil generally occuring within 24 hours after 
mechanical streching. In the chronic phase (3-6 months) involves arterial modeling, 
Thrombus formation and neointima hyperplasia. However, with balloon coronary 
angioplasty (POBA) and procedure those do not involve stent in an acute event result 
reduction of lumen diameter very rapidly. 
 
